Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University Hoth Also Expands Its' Intellectual Property to Further Its' Ma...
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to ...
Proton Intelligence Inc., developing the first-ever Continuous Potassium Monitoring (CKM™) platform, announced the closing of its $6.95 milli...
the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like pep...
Bristol Myers Squibb (NYSE: BMY) announced results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055), the pivotal Phase 3 trials evalua...
AstraZeneca’s Tagrisso (osimertinib) has been approved in the European Union (EU) for the treatment of adult patients with locally advanced...
A research led by Hong Kong Baptist University (HKBU) and the Shanghai Sixth People's Hospital Affiliated to School of Medicine at Shanghai Jiao ...
CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therap...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (v...
Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the fir...
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuxi...
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), announced that the first patient has been dosed in the pivotal Phase 3 Aspire study (NCT06617429) ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA™ (o...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct domains of Fa...
© 2025 Biopharma Boardroom. All Rights Reserved.
